Subscribe to RSS
DOI: 10.1055/s-0038-1637561
EARLY ONSET COLORRECTAL CANCER: PHENOTYPICAL FEATURES AND ENDOSCOPIC FOLLOW-UP AFTER SURGERY
Publication History
Publication Date:
27 March 2018 (online)
Aims:
To describe clinical and molecular characteristics of Early Onset Colorectal Cancer (EOCRC, < 45 years) and to identify high-risk groups for recurrence during surveillance after surgery.
Methods:
A retrospective cohort of 121 patients was included. Subgroups were formed according to the moment of detection of polyps in their follow-up at 10 years: Development of polyps at any time during the complete period of surveillance (group A), after 5 years (group B) within the first 5 years (group C) and no development of polyps (group D). Comparison of clinical and molecular variables between groups were made, including APC/p53 mutations and microsatellite instability (IMS).
Results:
Most frequent neoplasia locations were rectum (40.4%), left colon (35.5%) and right colon (23.1%). Primary lesions identified were Carcinoma in situ (CIS) (28,1%) and invasive adenocarcinoma (ADCA) (71, 9%) Non-Lynch familial aggregation was significantly associated to the development of polyps (51.9%, p = 0.001). Groups A and B included most of Lynch Syndrome patients (47.1% and 42.9% respectively). Patients in group A and B also showed greater total and disease-free survival. Group C included primarily patients with CIS and group D patients with ADCA (81.1%, p = 0.006). Patients with local or remote recurrence were distributed in groups C and D, with no differences in primary tumour location or mortality (61.5%). No significant association was identified between patients with APC/p53 mutation or IMS and the development of polyps.
Conclusions:
-
The most frequent locations were rectum and left colon, with histology of invasive ADCA.
-
Familial aggregation seems to be frequently associated with development of polyps
-
No relationship was found between APC, p53 and IMS mutations and development of polyps.
-
Better survival was found in groups with polyps at any time of follow-up or starting after 5 years.